Abstracts Archive - Page 2197 of 2607 - ACR Meeting Abstracts

Abstract Number: 559 • 2014 ACR/ARHP Annual Meeting
Ultra Sonographic Evaluation of the Anterior Chest Wall in Spondyloarthritis. a Prospective Study
Frank Verhoeven¹, Xavier Guillot², Marie Godfrin-Valnet³, Clément Prati⁴ and Daniel Wendling⁴, ¹Rheumatology, CHU jean Minjoz, Besançon, France, ²rheumatology, Besançon, France, ³Rheumatology, CHRU, Besançon, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: Anterior chest wall (ACW) involvement is a characteristic feature of spondyloarthritis (SpA), even in early stages, but its paraclinic exploration is not standardized.The aim…
Abstract Number: 558 • 2014 ACR/ARHP Annual Meeting
Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index
Philip J. Mease¹, Denis Poddubnyy², Su Chen³ and Jaclyn K. Anderson³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL
Background/Purpose: C-reactive protein (CRP), an objective measure of active inflammation, has been associated with obesity, with both overweight and obese individuals more likely to have…
Abstract Number: 557 • 2014 ACR/ARHP Annual Meeting
Translation and Cross-Cultural Adaptation of the ASAS Health Index and the environmental Item Set into 15 Languages
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen³, Wilson Bautista - Molano⁴, Ruben Burgos-Vargas⁵, Praveena Chiowchanwisawakit⁶, M Tuncay Duruoz⁷, Bassel El-Zorkany⁸, Inna Gaydukova⁹, Ivette Essers¹⁰, Pál Géher¹¹, Laure Gossec¹², Simeon Grazio¹³, Jieruo Gu¹⁴, Muhammad Asim Khan¹⁵, Tae.Jong Kim¹⁶, Walter P. Maksymowych¹⁷, Helena Marzo-Ortega¹⁸, Victoria Navarro-Compan¹⁹, Ignazio Olivieri²⁰, Dimos Patrikos²¹, Fernando Pimentel-Santos²², Filip van Den Bosch²³, Jane Zochling²⁴ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia, ⁵Rheumatology, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁶The Offices at Central World,, Siriraj Hospital, Bangkok, Thailand, ⁷Dept of PM&R, Rheumatology Clinic, Marmara Univ Med Schl, Istanbul, Turkey, ⁸Cairo University, Cairo, Egypt, ⁹Hospital Therapy, Saratov State Medical University, Saratov, Russia, ¹⁰School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ¹¹Budai Irgalmasrendi Korhaz, Budapest, Hungary, ¹²Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ¹³Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁴Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ¹⁵Medicine/ Rheumatology, CASE at MetroHealth Med Center, Cleveland, OH, ¹⁶Chonnam Nat`l University Medical School&Hospital, Chonnam, South Korea, ¹⁷Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁸University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ¹⁹University Hospital La Paz, Madrid, Spain, ²⁰Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²¹138 MESOGEION AVE & KATECHAKI, 401 Military Hospital Of Athens, Athens, Greece, ²²Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ²³Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²⁴Menzies Research Institute Tasmania, Hobart, Australia
Background/Purpose: The ASAS Health Index (ASAS HI) is a unidimensional questionnaire measuring health and impairment in functioning in patients with spondyloarthritis (SpA). The ASAS HI…
Abstract Number: 556 • 2014 ACR/ARHP Annual Meeting
Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling³, ¹Rheumatology, CHRU, Besançon, France, ²Investigation Center, CHRU, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: Spondyloarthritis (SpA) activity varies with time and treatment, but to date no clear definition of a flare of the disease is available. The aim…
Abstract Number: 555 • 2014 ACR/ARHP Annual Meeting
Urinary Excretion of Type II Collagen C-Telopeptide and Glucosyl-Galactosyl-Pyridinoline As Prognostic Biomarkers in Early Spondyloarthritis
Elisa Trujillo¹ and Maria del Mar Trujillo², ¹Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ²Servicio de evaluacion y planificacion, Servicio Canario de la Salud, Tenerife, Spain
Background/Purpose: The search for biomarkers in spondyloarthritis (SpA) is of great interest because of their diagnostic and prognostic role in the treatment of these diseases.…
Abstract Number: 554 • 2014 ACR/ARHP Annual Meeting
Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain
Maureen Dubreuil, Rheumatology, Boston VA HealthCare System, Boston, MA; Rheumatology, Boston University Medical Center, Boston, MA
Background/Purpose: Spondyloarthropathies (SpA) have been associated with increased risk of myocardial infarction (MI), however it remains unclear if the risk is related solely to…
Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Désirée van der Heijde², Nupun A. Varothai³ and Jaclyn K. Anderson³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³AbbVie Inc., North Chicago, IL
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…
Abstract Number: 552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis
Désirée van der Heijde¹, Manish Mittal², Naijun Chen², Aileen L. Pangan² and Avani D. Joshi², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL
Background/Purpose: In the ABILITY-1 trial, adalimumab (ADA) treatment for 12 weeks was associated with improved clinical and health-related quality of life (HRQOL) outcomes among patients…
Abstract Number: 551 • 2014 ACR/ARHP Annual Meeting
Predictors Associated with Rheumatologist Referral Time in Patients with Ankylosing Spondylitis
Atul A. Deodhar¹, Manish Mittal², Patrick Reilly², Yanjun Bao², Shivaji Manthena², Jaclyn K. Anderson² and Avani D. Joshi², ¹Oregon Health and Sciences University, Portland, OR, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Average delay between symptom onset and diagnosis of ankylosing spondylitis (AS) has been reported as 8–12.8 years1,2. This study assessed delay in AS diagnosis…
Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block
Amit Saxena¹, Peter M. Izmirly², Sung Won Han³, Andrew Markham⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Population Health, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB). Identification of maternal…
Abstract Number: 533 • 2014 ACR/ARHP Annual Meeting
Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren’s Syndrome
Kyung-Eun Lee¹, Dong-Jin Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose Chemokines, which control inflammatory cell migration, have been shown to play important roles in the inflammatory processes associated with Sjögren’s Syndrome (SS). CCL21 and…
Abstract Number: 532 • 2014 ACR/ARHP Annual Meeting
Adipose Tissue Is Prominent in Salivary Glands of Sjögren’s Syndrome Patients and Appears to Influence the Autoimmune Microenvironment in These Organs
Kathrine Skarstein^1,2, Lara Adnan Aqrawi³, Roland Jonsson^4,5 and Janicke Cecilie Liaaen Jensen⁶, ¹Gade Laboratorium for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, ²Department of Pathology, Haukeland University Hospital, Bergen, Norway, ³Department of Clinical Science, University of Bergen, Bergen, Norway, ⁴Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ⁵Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁶Department of Oral Surgery and Oral Medicine, University of Oslo, Oslo, Norway
Background/Purpose A positive salivary gland (SG) biopsy with a focus score of ≥1 is the only widely accepted pathological finding confirming the salivary gland component…
Abstract Number: 531 • 2014 ACR/ARHP Annual Meeting
Expression of Indoleamine 2,3 Dioxygenase-1 and -2 in Focal Sialoadenitis of Patients with Sjögren’s Syndrome
Claudio Vitali¹, Antonina Prafioriti², Domenico Sambataro³, Andrea Di Bernardo², Elisabetta Admiraglio², Saba Nayar⁴, Francesca Barone⁴ and Nicoletta Del Papa³, ¹Rheumatology Section, Istituto San Giuseppe, Como, Italy, ²Pathology Unit, Istituto G.Pini, Milan, Italy, ³Rheumatology Unit, Istituto G.Pini, Milan, Italy, ⁴Rheumatology Research Group, University of Birmingham Research Laboratories, University of Birmingham, Birmingham, United Kingdom
Background/Purpose The role of indoleamine 2,3 dioxygenase 1 and 2 (IDO1-IDO2) enzymes in modulating the immune response has not been so far completely clarified. IDO1…
Abstract Number: 530 • 2014 ACR/ARHP Annual Meeting
Downregulation of Microrna-183 in Sjogren’s Syndrome Minor Salivary Glands. Implications in Control of Ezrin Expression and Salivary Gland Function
Paola Perez Riveros¹, Mayank Tandon¹, Salman Kazmi², Alessia Gallo², Gabor G. Illei³ and Ilias Alevizos⁴, ¹Sjogren's Clinic, NIDCR, Bethesda, MD, ²NIH, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose Sjogren’s syndrome (SS) is an exocrinopathy, which is mainly characterized by salivary glands (SG) hypofunction. SGs from SS patients present dilated lumen in acini…
Abstract Number: 529 • 2014 ACR/ARHP Annual Meeting
IP3R3 Deficit Underlies the Loss of Fluid Secretion in Salivary Glands from Sjögren’s Syndrome Patients
Leyla Y Teos¹, Bill Swaim², Margaret Grisius³, Ana Paola Cotrim¹, Shyh-Ing Jang⁴, Lolita Bebris³, David Yule⁵, Gabor G. Illei⁶, Indu Ambudkar⁷ and Ilias Alevizos⁸, ¹NIDCR, NIH, Bethesda, MD, ²Mptb, NIH/NIDCR, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD, ⁵Pharmacology and Physiology,, University of Rochester, Rpochester, NY, ⁶Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁷NIDCR, MPTB, NIH, Bethesda, MD, ⁸Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD
Background/Purpose Sjögren’s syndrome (SS) is a chronic autoimmune disease with unknown etiology. Affecting from 0.2% to 3.0% of the total population, with a 9:1 female…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].